![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Singapore, November 12, 2024 — Federal Express Corporation (FedEx), one of the world’s largest express transportation companies, has expanded its state-of-the-art Life Science Center in Gimpo, Gyeonggi-do, Korea. This strategic enhancement, along with FedEx Life Science Centers in Singapore and Japan, is addressing the rising demand for a robust logistics network with advanced capabilities to support the rapidly growing healthcare industry across the Asia Pacific region.
The advanced FedEx Korea Life Science Center spans 2,288 square meters – almost triple the size of the previous facility. The new operation includes five temperature-controlled areas for temperatures ranging from -150°C to +25°C, which are monitored 24/7 to ensure continuous compliance with pharmaceutical cold chain requirements. The facility is also Korea Good Supply Practice (KGSP)- certified, in accordance with market-specific quality and regulatory requirements for the healthcare industry. Along with temperature-controlled Inventory management capabilities, the Korea Life Science Center is equipped to support both domestic and international transportation needs.
By expanding its capacity, FedEx is strengthening its life sciences logistics expertise, ensuring seamless and reliable transportation of critical healthcare shipments including investigational medicinal products (IMP), biological samples, and biopharmaceutical product lines while enabling pharmaceutical and clinical trials customers to prioritize patient care.
The pharmaceutical market in Asia Pacific is projected to reach USD 290 billion by 2028. Additionally, the region accounts for approximately 50% of global clinical trials, highlighting it
increasing role in global pharmaceutical research and development. Customers in the healthcare and pharmaceutical sector need precise, temperature-controlled services to preserve product efficacy. With decades of experience, FedEx provides expertise in specialized healthcare and clinical trial solutions, enabled by its international Express network, customized Time Critical Special Services (SpS), and a global network of Life Science Centers with locations in Korea, Singapore, Tokyo (Japan), Mumbai (India), Memphis (United States), and Veldhoven (the Netherlands). The company’s extensive healthcare infrastructure also includes 130+ cold-chain facilities worldwide, ensuring continuous temperature integrity for shipments moving through our domestic and international networks.
“Asia Pacific’s healthcare sector is evolving at an unprecedented pace, driven by demographic shifts, infrastructure investments, and rapid tech advancements,” said Kawal Preet, president, Asia Pacific at FedEx. “At FedEx, we are leveraging our decades of healthcare expertise, extensive global network and differentiated solutions to propel this growth. Through strategic investments in cutting- edge facilities and AI-driven smart logistics, we are reshaping healthcare supply chains and enabling the future of life sciences research and business innovation across the region.”
FedEx Clinical Care, part of the company’s portfolio of dedicated healthcare transportation solutions, provides end-to-end delivery capabilities for time and temperature-sensitive healthcare shipments. This service ensures expedited delivery within 24 to 48 hours, leveraging specialized features including temperature-controlled packaging, priority handling and clearance, and 24/7 monitoring and intervention using sensor based real-time tracking.
Recently, FedEx was recognized for ‘Innovation in Clinical Supply Chain Logistics’ at the Korea Biopharma Excellence Awards 2024 for exceptional contribution to clinical supply chains in Korea. In August, the company introduced FedEx Surround®, an innovative monitoring and intervention solution for enhanced control and visibility for healthcare and other critical shipments.
For more information on FedEx healthcare solutions, please visit https://fedexbusinessinsights.com/healthcare/
